The IDA treatment significantly decreased cell growth in dose-dependent effects; blockade of Tim-3 expression on AML blasts significantly reduced the IDA-mediated suppression of cell growth (Figure 3B). Here, HAVCR2 is linked to acute myeloid leukemia.